Skip Navigation Links
SEARCH  



 
Bookmark and Share
Spectrum Pharmaceuticals Announces that the FDA is Deferring its Action on the BLA for ROLONTIS® (eflapegrastim)
Agency cites inability to conduct inspection of the drug substance manufacturing facility due to COVID-19 related travel restrictions HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on ...

Full "IntellAsia: Resources" article




Disclaimer | Terms Of Use And Privacy Statement


© Metals News. All rights reserved.